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AIMS: Amyloid-beta (Abeta) deposits and intraneuronal hyperphosphorylated tau 
are major pathological hallmarks of Alzheimer’s disease (AD). The coexistence 
of these aggregates in AD brains leads to synaptic dysfunction, neuronal loss and 
cognitive decline. Failures in protein homeostasis, along with defective glial 
responses, have been identified as pathological mechanisms linked to this 
disorder. Thus, our main objective is to better understand the differential impact 
of Abeta- and tau-aggregates to these processes in the hippocampus of AD 
models.  
METHODS: We analyzed APP- (APPSL/PS1M146L) and Tau- (ThyTau22 and 
hP301S) based models from 2 to 18 months of age. Tau and Abeta pathologies 
were assessed by western blotting and immunohistochemistry. Confocal 
microscopy was used to study microglia/aggregates relationship. Levels of 
synaptic proteins, autophagy and inflammatory markers were determined by 
quantitative PCR, WB and immunohistochemistry.  
RESULTS: Tau and Abeta pathologies initiated as early as 2 months of age and 
increased progressively with aging. Even though only APP/PS1 hippocampus 
showed dystrophic neurites positive to  proteostatic and presynaptic markers, 
their protein levels were altered in both types of models from 6-9 months 
compared to age-matched WT mice.  Inflammatory markers and microglial 
reactivity were barely increased in the hippocampus of ThyTau mice in contrast 
to P301S and APP/PS1 mice which displayed a prominent microglial response. 
CONCLUSIONS: Clarifying the effects of Abeta and tau separately would indeed 
enable the development of novel therapeutic strategies and drugs targeting 
pathways related to these proteinopathies.  
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